Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial
Heiss WD, Brainin M, Bornstein NM, Tuomilehto J, Hong Z, Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators · 2012 · Stroke · PMID 22282884
What does this source report?
The combined primary outcome showed no significant benefit. A favorable signal in more severe strokes arose in post-hoc analysis.
- Population and setting
- CASTA: 1,070 acute ischemic-stroke patients; randomized within 12 hours; 90-day follow-up
- Evidence type
- Randomized trial
- Preparation
- See the original report; formulation details require verification.
- Source language
- English
- Title provenance
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
What are the limitations?
- The severe-stroke subgroup is exploratory, not confirmation of efficacy.
- Do not count this trial again when reading meta-analyses that include CASTA.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Review depth: Abstract reviewed
Source access and review scope
Indexed citation and abstract reviewed via Europe PMC / PubMed; full methods and risk of bias not comprehensively appraised.
Recorded source-check date: 2026-10-05. This date does not imply a completed systematic review.
Cite and trace this record
Original source: Heiss WD, Brainin M, Bornstein NM, Tuomilehto J, Hong Z, Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial Stroke · PMID 22282884 2012.
Molekul research summary: https://molekul.io/research/stroke-22282884. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry